Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06647888 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Evaluation of Enavogliflozin's Efficacy and Safety in Type II Diabetes With Hypertension or Dyslipidemia

StatusRecruiting
PhaseNot specified
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated January 23, 2025 (before its estimated December 31, 2025 completion). Its status may not reflect the trial's current state.

Record History

  1. Trial status: Not Yet Recruiting to Recruiting Study sites: 0 to 1 · Start date changed from estimate of Dec 2, 2024 to Dec 3, 2024 · Study title shortened, about 6 wordsv4 Show 3 more changesShow less
    • Study sites: 0 to 1
    • Start date changed from estimate of Dec 2, 2024 to Dec 3, 2024
    • Study title shortened, about 6 words

    See this version in full on ClinicalTrials.gov ↗

  2. Re-verified, no change to tracked fieldsv3
  3. Interventions: Enavogliflozin (Drug), Enavogliflozin (Drug) to Envlo Tablet (Drug), Envlomet SR Tablet (Drug)v2
  4. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This observational study is a non-interventional, multi-center, prospective observational study aimed at tracking the efficacy and safety of Envlo or Envlomet SR tablets for 24 weeks in patients with type 2 diabetes and hypertension or dyslipidemia who are currently taking or are scheduled to take Envlo or Envlomet SR tablets in an actual clinical setting.
Trial Details
NCT Number NCT06647888
Lead Sponsor Daewoong Pharmaceutical Co. LTD.
Conditions Diabetes Mellitus, Type 2
Enrollment 12,000 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov